Positron emission tomography in CNS drug discovery and drug monitoring

Journal of Medicinal Chemistry

Volumn 57, Issue 22, 2014, Pages 9232-9258

  Piel, Markus ^a   Vernaleken, Ingo ^b   Rösch, Frank ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR; NEUROLEPTIC AGENT; TRACER; CENTRAL NERVOUS SYSTEM AGENTS; DOPAMINE; DRUG; GLUTAMIC ACID; SEROTONIN RECEPTOR;

ARTICLE; CENTRAL NERVOUS SYSTEM; COMPARTMENT MODEL; DOPAMINERGIC SYSTEM; DRUG DESIGN; DRUG DEVELOPMENT; DRUG MONITORING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HYBRID; MOLECULAR IMAGING; PHARMACOPHORE; POSITRON EMISSION TOMOGRAPHY; PSYCHIATRY; SCHIZOPHRENIA; ANIMAL; BRAIN; CHEMICAL MODEL; CHEMISTRY; DRUG EFFECTS; GLYCOLYSIS; PERMEABILITY; PROCEDURES;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM AGENTS; DOPAMINE; DRUG DISCOVERY; DRUG MONITORING; GLUTAMIC ACID; GLYCOLYSIS; HUMANS; MODELS, CHEMICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA;

EID: 84913593388     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5001858     Document Type: Article

References (161)

1. Phelps, M. E. Positron emission tomography provides molecular imaging of biological processes Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 9226-9233
2. Rahmim, A.; Zaidi, H. PET versus SPECT: strengths, limitations and challenges Nucl. Med. Commun. 2008, 29, 193-207
3. Qaim, S. M. Cyclotron production of medical radionuclides. In Handbook of Nuclear Chemistry, 2 nd ed.; Vértes, A.; Nagy, S.; Klencsár, Z.; Lovas, R. G.; Rösch, F., Eds.; Springer: Dordrecht, The Netherlands, 2011; pp 1903-1933.
4. PET Drugs-Current Good Manufacturing Practice (CGMP); U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Silver Spring, MD, 2011; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM266640.pdf.
5. Norenberg, J. P.; Schwarz, S.; VanBrocklin, H. FDA cGMP requirements for PET drugs J. Nucl. Med. 2011, 52, 16N
6. Ache, H. J. Chemistry of the positron and of positronium Angew. Chem., Int. Ed. 1972, 11, 179-199
7. Watabe, H.; Matsumoto, K.; Senda, M.; Iida, H. Performance of list mode data acquisition with ECAT EXACT HR and ECAT EXACT HR positron emission scanners Ann. Nucl. Med. 2006, 20, 189-194
8. 18F] 2-deoxy-2-fluoro- d -glucose J. Nucl. Med. 1978, 19, 1154-1161
9. Reig, S.; Penedo, M.; Gispert, J. D.; Pascau, J.; Sanchez-Gonzalez, J.; Garcia-Barreno, P.; Desco, M. Impact of ventricular enlargement on the measurement of metabolic activity in spatially normalized PET NeuroImage 2007, 35, 748-758
10. Garnett, E. S.; Firnau, G.; Nahmias, C.; Chirakal, R. Striatal dopamine metabolism in living monkeys examined by positron emission tomography Brain Res. 1983, 280, 169-171
11. Kumakura, Y.; Cumming, P. PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches Neuroscientist 2009, 15, 635-650
12. Innis, R. B.; Cunningham, V. J.; Delforge, J.; Fujita, M.; Gjedde, A.; Gunn, R. N.; Holden, J.; Houle, S.; Huang, S. C.; Ichise, M.; Iida, H.; Ito, H.; Kimura, Y.; Koeppe, R. A.; Knudsen, G. M.; Knuuti, J.; Lammertsma, A. A.; Laruelle, M.; Logan, J.; Maguire, R. P.; Mintun, M. A.; Morris, E. D.; Parsey, R.; Price, J. C.; Slifstein, M.; Sossi, V.; Suhara, T.; Votaw, J. R.; Wong, D. F.; Carson, R. E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands J. Cereb. Blood Flow Metab. 2009, 27, 1533-1539
13. Griffeth, L. K. Use of PET/CT scanning in cancer patients: technical and practical considerations Proc. (Bayl. Univ. Med. Cent.) 2005, 18, 321-330
14. Catana, C.; Drzezga, A.; Heiss, W.-D.; Rosen, B. R. PET/MRI for neurologic applications J. Nucl. Med. 2012, 53, 1916-1925
15. Rösch, F. Radiochemistry and radiopharmaceutical chemistry in life sciences. In Handbook of Nuclear Chemistry, 2 nd ed.; Vértes, A.; Nagy, S.; Klencsár, Z.; Lovas, R. G.; Rösch, F., Eds.; Springer, Dordrecht, The Netherlands, 2011.
16. Saha, G. B. Basics of PET Imaging; Springer: New York, 2005.
17. Virdee, K.; Cumming, P.; Caprioli, D.; Jupp, B.; Rominger, A.; Aigbirhio, F. I.; Fryer, T. D.; Riss, P. J.; Dalley, J. W. Applications of positron emission tomography in animal models of neurological and neuropsychiatric disorders Neurosci. Biobehav. Rev. 2012, 36, 1188-1216
18. Frankle, W. G.; Slifstein, M.; Talbot, P. S.; Laruelle, M. Neuroreceptor imaging in psychiatry: theory and applications Neuroimaging, Part B 2005, 67, 385-440
19. Gründer, G. Molecular Imaging in the Clinical Neurosciences; Humana Press: New York, 2012.
20. Fischer, K.; Sossi, V.; Schmid, A.; Thunemann, M.; Maier, F. C.; Judenhofer, M. S.; Mannheim, J. G.; Reischl, G.; Pichler, B. J. Noninvasive nuclear imaging enables the in vivo quantification of striatal dopamine receptor expression and raclopride affinity in mice J. Nucl. Med. 2011, 52, 1133-1141
21. Hume, S. P.; Gunn, R. N.; Jones, T. Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals Eur. J. Nucl. Med. 1998, 25, 173-176
22. Meanwell, N. A. Synopsis of some recent tactical application of bioisoteres in drug design J. Med. Chem. 2011, 54, 2529-2591
23. Kilbourn, M. R. Fluorine-for-hydrogen: a strategy for radiolabeling, not a replacement Nucl. Med. Biol. 2013, 40, 956-958
24. 11C-N-methyl-spiperone Acta Neurol. Scand. 1987, 75, 87-94
25. 18F labeled spiperone analog for positron emission tomographic studies of the dopamine receptor Nucl. Med. Biol. 1998, 15, 83-97
26. Kilbourn, M. R.; Pavia, M. R.; Gregor, V. E. Synthesis of fluorine-18 labeled GABA uptake inhibitors Int. J. Radiat. Appl. Instrum., Part A 1990, 41, 823-828
27. 18F]-labeled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia Bioorg. Med. Chem. 2001, 9, 665-675
28. 18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure Appl. Radiat. Isot. 2001, 54, 73-80
29. 18F]trifluoromethyl groups Chem. Commun. 2011, 47, 11873-11875
30. 18F]trifluoromethylation of aryl and heteroaryl iodides for PET imaging Nat. Chem. 2013, 5, 941-944
31. 18F]DMFP infusions Synapse 2012, 66, 705-713
32. 2A receptors with positron emission tomography Life Sci. 1996, 58, 187-192
33. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26
34. Zhang, L.; Villalobos, A.; Beck, E. M.; Bocan, T.; Chappie, T. A.; Chen, L.; Grimwood, S.; Heck, S. D.; Helal, C. J.; Hou, X.; Humphrey, J. M.; Lu, J.; Skaddan, M. B.; McCarthy, T. J.; Verhoest, P. R.; Wager, T. T.; Zasadny, K. Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand J. Med. Chem. 2013, 56, 4568-4579
35. Dutheil, F.; Dauchy, S.; Diry, M.; Sazdovitch, V.; Cloarec, O.; Mellottée, L.; Bièche, I.; Ingelman-Sundberg, M.; Flinois, J. P.; de Waziers, I.; Beaune, P.; Declèves, X.; Duyckaerts, C.; Loriot, M. A. Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function Drug Metab. Dispos. 2009, 37, 165-174
36. Bartmann, H.; Fuest, C.; la Fougere, C.; Xiong, G.; Just, T.; Schlichtiger, J.; Winter, P.; Boning, G.; Wängler, B.; Pekcec, A.; Soerensen, J.; Bartenstein, P.; Cumming, P.; Potschka, H. Imaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus: proof-of-concept in a chronic rat model of temporal lobe epilepsy Epilepsia 2010, 51, 1780-1790
37. Tournier, N.; Valette, H.; Peyronneau, M. A.; Saba, W.; Goutal, S.; Kuhnast, B.; Dollé, F.; Scherrmann, J. M.; Cisternino, S.; Bottlaender, M. Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening J. Nucl. Med. 2011, 52, 415-423
38. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents J. Med. Chem. 2003, 46, 2740-2754
39. Klunk, W. E.; Engler, H.; Nordberg, A.; Wang, Y.; Blomqvist, G.; Holt, D. P.; Bergström, M.; Savitcheva, I.; Huang, G. F.; Estrada, S.; Ausén, B.; Debnath, M. L.; Barletta, J.; Price, J. C.; Sandell, J.; Lopresti, B. J.; Wall, A.; Koivisto, P.; Antoni, G.; Mathis, C. A.; Longström, B. Imaging brain amyloid in Alzheimer's disease with Pittsburg Compound-B Ann. Neurol. 2004, 55, 306-319
40. Klunk, W. E.; Mathis, C. A., Jr.; Wang, Y. Benzothiazole Derivative Compounds, Compositions and Uses. Patent WO2004083195 A1, 2004; p 134.
41. 11C]PIB across the spectrum of Alzheimer's disease Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 290-300
42. Mathis, C. A.; Mason, N. S.; Lopresti, B. J.; Klunk, W. E. Development of positron emission tomography beta-amyloid plaque imaging agents Semin. Nucl. Med. 2012, 42, 423-432
43. Barthel, H.; Sabri, O. Florbetaben to trance amyloid-β in the Alzheimer brain by means of PET J. Alzheimer's Dis. 2011, 26, 117-121
44. 18F-AV-45 (flobetapir F-18) J. Nucl. Med. 2010, 51, 913-920
45. Lopéz-Muñoz, F.; Alamos, C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice Brain Res. Bull. 2009, 79, 130-141
46. Berger, J. R.; Choi, D.; Kaminski, H. J.; Gordon, M. F.; Hurko, O.; D'Cruz, O. N.; Pleasure, S. J.; Feldman, E. L. Importance and hurdles to drug discovery for neurological disease Ann. Neurol. 2013, 74, 441-446
47. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products; U.S. Food and Drug Administration: Silver Spring, MD, 2004; http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm.
48. The Pharmaceutical Industry in Figures; European Federation of Pharmaceutica Industries and Associations: Brussels, Belgium, 2013; http://www.efpia.eu/uploads/Modules/Documents/figures-key-data-2013.pdf.
49. Woodcock, J.; Woosley, R. The FDA critical path initiative and its influence on new drug development Annu. Rev. Med. 2008, 59, 1-12
50. Annual R&D General Metrics Study Highlights: New Success Rate and Cycle Time Data. https://www.kmrgroup.com/PressReleases/2012-08-08%20KMR%20PBF%20Success%20Rate%20&%20Cycle%20Time%20Press%20Release.pdf.
51. Matsuoka, N.; Ainer, T. G. FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel potential antidementia drug, improves visual recognition memory in rhesus monkeys: comparison with physostigmine J. Pharmacol. Exp. Ther. 1997, 280, 1201-1209
52. Noda, A.; Takamatsu, H.; Murakami, Y.; Yajima, K.; Tatsumi, M.; Ichise, R.; Nishimura, S. Measurement of brain concentration of FK960 for development of a novel antidementia drug: a PET study in conscious rhesus monkeys J. Nucl. Med. 2003, 44, 105-108
53. 2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia Int. J. Neuropsychopharmacol. 2004, 7, 421-430
54. 11C]-(+)-PHNO positron emission tomography study Neuropsychopharmacology 2008, 33, 279-289
55. London, E. D.; Cascella, N. G.; Wong, D. F.; Philips, R. L.; Dannals, R. F.; Links, J. M.; Herning, R.; Grayson, R.; Jaffe, J. H.; Wagner, H. N. Cocaine-induced reduction of glucose utilization in human brain Arch. Gen. Psychiatry 1990, 47, 567-574
56. Bartzokis, G.; Beckson, M.; Newton, T.; Mandelkern, M.; Mintz, J.; Foster, J. A.; Ling, W.; Bridge, T. P. Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria Neuropsychopharmacology 1999, 20, 583-590
57. 11C]MK-4232: the first positron emission tomography tracer for the calcitonin gene-related peptide receptor ACS Med. Chem. Lett. 2013, 4, 863-868
58. 11C]MK-4232 J. Pharmacol. Exp. Ther. 2013, 347, 478-486
59. 11C: Labeling chemistry and labeled compounds. In Handbook of Nuclear Chemistry, 2 nd ed.; Vértes, A.; Nagy, S.; Klencsár, Z.; Lovas, R. G.; Rösch, F., Eds.; Springer: Dordrecht, The Netherlands, 2011; pp 1977-2019.
60. Müller, K.; Faeh, C.; Diederich, F. Fluorine in pharmaceuticals: looking beyond intuition Science 2007, 317, 1881-1886
61. 18F: labeling chemistry and labeled compounds. In Handbook of Nuclear Chemistry, 2 nd ed.; Vértes, A.; Nagy, S.; Klencsár, Z.; Lovas, R. G.; Rösch, F., Eds.; Springer: Dordrecht, The Netherlands, 2011; pp 2021-2071.
62. Snyder, S. E.; Kilbourn, M. R. Chemistry of fluorine-18 radiopharmaceuticals. In Handbook of Radiopharmaceuticals, Radiochemistry and Applications; Welch, M. J.; Redvanly, C. S., Eds.; Wiley & Sons Ltd, New York, 2003; pp 195-228.
63. Beattie, D. T.; Beresford, I. J.; Connor, H. E.; Marshall, F.; Hancock, A. B.; Hagan, R. M.; Bowers, J.; Birch, P. J.; Ward, P. The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist Br. J. Pharmacol. 1995, 116, 3149-3157
64. Gardner, C. J.; Armour, D. R.; Beattie, D. T.; Gale, J. D.; Hawcock, A. B.; Kilpatrick, G. J.; Twissell, D. J.; Ward, P. GR 205171: A novel antagonist with high affinity for the tachykinin NK-1 receptor and potent broad-spectrum anti-emetic activity Regul. Pept. 1996, 65, 45-53
65. Muñoz, M.; Coveñaz, R. NK-1 receptor antagonists: a new paradigm in pharmacological therapy Curr. Med. Chem. 2011, 18, 1820-1831
66. 11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171-PET studies in rhesus monkey Neuropharmacology 2000, 39, 664-670
67. Quartara, L.; Altamura, M. Tachykinin receptors antagonists: from research to clinic Curr. Drug Targets 2006, 7, 975-992
68. Hurko, O.; Ryan, J. L. Translational research in central nervous system drug discovery NeuroRx 2005, 2, 671-682
69. Passchier, J.; Gee, A.; Willemsen, A.; Vaalburg, W.; van Waarde, A. Measuring drug-related receptor occupancy with positron emission tomography Methods 2002, 27, 278-286
70. 2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone J. Pharmacol. Exp. Ther. 2012, 341, 81-89
71. 2C receptor antagonists EMD 281014 and SB- 243213, respectively, on sleep and waking in the rat Eur. J. Pharmacol. 2006, 553, 163-167
72. Adamec, R.; Creamer, K.; Bartoszyk, G. D.; Burton, P. Prophylactic and therapeutic effects of acute systemic injections of EMD 281014, a selective serotonin 2A receptor antagonist on anxiety induced by predator stress in rats Eur. J. Pharmacol. 2004, 504, 79-96
73. 2 antagonist in humans: a dose-finding PET study Psychopharmacology 2004, 175, 382-388
74. 2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography Neuropsychopharmacology 1997, 17, 175-185
75. 18F]fallypride positron emission tomography study Biol. Psychiatry 2011, 70, 770-776
76. 1A receptors with position emission tomography Life Sci. 1994, 55, 403-407
77. 11C]WAY-100,635 Eur. J. Pharmacol. 1995, 283, R1-3
78. 11C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET Nucl. Med. Biol. 1996, 23, 627-634
79. 11C]WAY-100635 in humans: comparison of arterial and reference tissue input functions J. Cereb. Blood Flow Metab. 2000, 20, 1111-1133
80. 11C]WAY-100635 Eur. J. Pharmacol. 1996, 301, R5-7
81. Dahlström, A.; Fuxe, F. Evidence for the existence of monoamine-containing neurons in the central nervous system Acta Physiol. Scand. 1964, 62, 1-55
82. Seamans, J. K.; Yang, C. R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex Prog. Neurobiol. 2004, 74, 1-58
83. Durstewitz, D.; Seamans, J. K.; Sejnowski, T. J. Dopamine-mediated stabilization of delay-period activity in a network model of prefrontal cortex J. Neurophysiol. 2000, 83, 1733-1750
84. Carlsson, A.; Lindqvist, M. Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine on mouse brain Acta Pharmacol. Toxicol. 1963, 20, 140-144
85. Costall, B.; Naylor, R. J. Detection of the neuroleptic properties of clozapine, sulpiride and thioridazine Psychopharmacology 1975, 43, 69-74
86. Angst, J.; Bente, D.; Berner, P.; Heimann, H.; Helmchen, H.; Hippius, H. Das klinische Wirkungsbild von Clozapin Pharmakopsychiatrie 1971, 4, 201-221
87. 3H]dopa in various regions of the brain J. Neurochem. 1966, 13, 655-669
88. 18F]5-fluoro-DOPA with reactor-produced fluorine-18 Int. J. Appl. Radiat. Isot. 1973, 24, 182-184
89. 18F]fluorodopamine: initial findings in humans J. Am. Coll. Cardiol. 1993, 22, 1961-71
90. Cumming, P.; Gjedde, A. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms Synapse 1998, 29, 37-61
91. Weeks, R. A.; Brooks, D. J. Positron emission tomography and central neurotransmitter systems in movement disorders Fundam. Clin. Pharmacol. 1994, 8, 503-517
92. Snow, B. J.; Nygaard, T. G.; Takahashi, H.; Calne, D. B. Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism Ann. Neurol. 1993, 34, 733-738
93. Frankle, W. G. Neuroreceptor imaging studies in schizophrenia Harv. Rev. Psychiatry 2007, 15, 212-232
94. Sossi, V.; Doudet, D. J.; Holden, J. E. A reversible tracer analysis approach to the study of effective dopamine turnover J. Cereb. Blood Flow Metab. 2001, 21, 469-476
95. Cumming, P.; Munk, O. L.; Doudet, D. Loss of metabolites from monkey striatum during PET with FDOPA Synapse 2001, 41, 212-218
96. 18F]fluorodopamine storage capacity J. Cereb. Blood Flow Metab. 2005, 25, 807-819
97. 18F]fluorodopa/positron emission tomography study J. Neurosci. 2007, 27, 8080-8087
98. Gründer, G.; Vernaleken, I.; Muller, M. J.; Davids, E.; Heydari, N.; Buchholz, H. G.; Bartenstein, P.; Munk, O. L.; Stoeter, P.; Wong, D. F.; Gjedde, A.; Cumming, P. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo Neuropsychopharmacology 2003, 28, 787-794
99. 18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: a positron emission tomography study in healthy subjects Neuroimage 2008, 40, 1222-1231
100. 18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge NeuroImage 2006, 30, 1332-1339
101. Danielsen, E. H.; Smith, D.; Hermansen, F.; Gjedde, A.; Cumming, P. Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo Synapse 2001, 41, 172-175
102. Sharma, R. P.; Javaid, J. I.; Janicak, P. G.; Davis, J. M.; Faull, K. Homovanillic acid in the cerebrospinal fluid: patterns of response after four weeks of neuroleptic treatment Biol. Psychiatry 1993, 34, 128-134
103. Egerton, A.; Chaddock, C. A.; Winton-Brown, T. T.; Bloomfield, M. A.; Bhattacharyya, S.; Allen, P.; McGuire, P. K.; Howes, O. D. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort Biol. Psychiatry 2013, 74, 106-112
104. Howes, O. D.; Montgomery, A. J.; Asselin, M. C.; Murray, R. M.; Valli, I.; Tabraham, P.; Bramon-Bosch, E.; Valmaggia, L.; Johns, L.; Broome, M.; McGuire, P. K.; Grasby, P. M. Elevated striatal dopamine function linked to prodromal signs of schizophrenia Arch. Gen. Psychiatry 2009, 66, 13-20
105. Allen, P.; Luigjes, J.; Howes, O. D.; Egerton, A.; Hirao, K.; Valli, I.; Kambeitz, J.; Fusar-Poli, P.; Broome, M.; McGuire, P. Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals Schizophr. Bull. 2012, 38, 1268-1276
106. Weinberger, D. R.; Laruelle, M. Neurochemical and neuropharmacological imaging in schizophrenia. In Neuropharmacology: The Fifth Generation of Progress; Davis, K. L.; Charney, D. S.; Coyle, J. T.; Nemeroff, C., Eds.; Lippincott, Williams, & Wilkins: Philadelphia, PA, 2001.
107. 2 receptor binding in the anterior cingulate cortex in schizophrenia Arch. Gen. Psychiatry 2002, 59, 25-30
108. 2 receptor binding in subregions of the thalamus in schizophrenia Am. J. Psychiatry 2004, 161, 1016-1022
109. 3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia Schizophr. Res. 2006, 85, 232-244
110. 2/3-receptor availability in schizophrenia decreases with progression of psychosis J. Nucl. Med. 2009, 50, 80
111. Haase, H.-J. Die Dosierung der Neuroleptika unter feinmotorischer Kontrolle als konstruktiver Beitrag zum Thema der "Pharmakeule". In Psychopharmakotherapie. Optimale Dosierung der Neuroleptika; Haase, H.-J., Ed.; Perimed: Erlangen, 1982.
112. 76Br]bromospiperone binding sites demonstrated by positron emission tomography in progressive supranuclear palsy J. Cereb. Blood Flow Metab. 1986, 6, 131-136
113. Cambon, H.; Baron, J. C.; Boulenger, J. P.; Loc'h, C.; Zarifian, E.; Maziere, B. In vivo assay for neuroleptic receptor binding in the striatum. Positron tomography in humans Br. J. Psychiatry 1987, 151, 824-830
114. 2-dopamine receptors studied by PET-a comparison to the equilibrium analysis J. Cereb. Blood Flow Metab. 1989, 9, 696-708
115. Baron, J. C.; Martinot, J. L.; Cambon, H.; Boulenger, J. P.; Poirier, M. F.; Caillard, V.; Blin, J.; Huret, J. D.; Loc'h, C.; Maziere, B. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels Psychopharmacology 1989, 99, 463-472
116. 11C-labelled raclopride, a new potent dopamine receptor antagonist: preliminary PET studies of cerebral dopamine receptors in the monkey Int. J. Appl. Radiat. Isot. 1985, 36, 269-273
117. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs Arch. Gen. Psychiatry 1988, 45, 71-76
118. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients Biol. Psychiatry 1993, 33, 227-235
119. 2 dopamine receptor occupancy in relation to extrapyramidal syndromes in patients being treated with neuroleptic drugs Psychopharmacol. Ser. 1993, 10, 94-100
120. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects Arch. Gen. Psychiatry 1992, 49, 538-544
121. Shintomi, K.; Yamamura, M. Letter: Effects of antiparkinsonian drugs on neuroleptic-induced extrapyramidal signs in monkeys J. Pharm. Pharmacol. 1973, 25, 666-667
122. Meltzer, H. Y.; Matsubara, S.; Lee, J. C. The ratios of serotonin and dopamine affinities differentiate atypical and typical antipsychotic drugs Psychopharmacol. Bull. 1989, 25, 390-392
123. 2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone Am. J. Psychiatry 2004, 161, 818-825
124. 2A receptor occupancy in schizophrenic patients Am. J. Psychiatry. 1999, 156, 869-875
125. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia Am. J. Psychiatry 1999, 156, 286-293
126. 2A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography Psychopharmacology 2013, 225, 329-339
127. 2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects Psychopharmacology 2013, 229, 245-252
128. Potkin, S. G.; Keator, D. B.; Kesler-West, M. L.; Nguyen, D. D.; van Erp, T. G.; Mukherjee, J.; Shah, N.; Preda, A. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder CNS Spectr. 2013, 1-6
129. Muller, M. J.; Regenbogen, B.; Hartter, S.; Eich, F. X.; Hiemke, C. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia J. Psychiatr. Res. 2007, 41, 673-679
130. 2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients J. Psychopharmacol. 2008, 22, 8828-8894
131. 2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas Int. J. Neuropsychopharmacol. 2010, 13, 951-960
132. 7 receptor in the rat brain Bioorg. Med. Chem. 2013, 21, 5316-5322
133. 1A) receptors in the central nervous system Eur. J. Nucl. Med. 2001, 28, 113-129
134. Costall, B.; Naylor, R. J. A comparison of the abilities of typical neuroleptic agents and of thioridazine, clozapine, sulpiride and metoclopramide to antagonise the hyperactivity induced by dopamine applied intracerebrally to areas of the extrapyramidal and mesolimbic systems Eur. J. Pharmacol. 1976, 40, 9-19
135. 123I]epidepride SPET study of amisulpride-treated patients Am. J. Psychiatry 2003, 160, 1413-1420
136. 2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia Int. J. Neuropsychopharmacol. 2004, 7, 421-430
137. 7 antagonist: relevance for antidepressant actions in vivo Psychopharmacol. 2009, 205, 119-128
138. Pilowsky, L. S.; Mulligan, R. S.; Acton, P. D.; Ell, P. J.; Costa, D. C.; Kerwin, R. W. Limbic selectivity of clozapine Lancet 1997, 350, 490-491
139. 123I]-epidepride SPET study J. Clin. Psychopharmacol. 2003, 23, 5-14
140. 3 receptor-binding profile of clozapine in patients with schizophrenia Neuropsychopharmacology 2006, 31, 1027-1035
141. 18F]fluoropropyl)-2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer Nucl. Med. Biol. 1995, 22, 283-296
142. 18F]fallypride PET study Am. J. Psychiatry 2008, 165, 988-995
143. Lawler, C. P.; Prioleau, C.; Lewis, M. M.; Mak, C.; Jiang, D.; Schetz, J. A.; Gonzalez, A. M.; Sibley, D. R.; Mailman, R. B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes Neuropsychopharmacology 1999, 20, 612-627
144. Swainston Harrison, T.; Perry, C. M. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder Drugs 2004, 64, 1715-1736
145. 2 receptors in antipsychotic response - a double-blind PET study in schizophrenia Neuropsychopharmacology 2007, 32, 1209-1215
146. Carlsson, A.; Hansson, L. O.; Waters, N.; Carlsson, M. L. A glutamatergic deficiency model of schizophrenia Br. J. Psychiatry Suppl. 1999, 2-6
147. Andreasen, N. C.; O'Leary, D. S.; Flaum, M.; Nopoulos, P.; Watkins, G. L.; Boles Ponto, L. L.; Hichwa, R. D. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients Lancet 1997, 349, 1730-1734
148. Javitt, D. C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia Hillside J. Clin. Psychiatry 1987, 9, 12-35
149. Krystal, J. H.; D'Souza, D. C.; Karper, L. P.; Bennett, A.; Abi-Dargham, A.; Abi-Saab, D.; Cassello, K.; Bowers, M. B., Jr.; Vegso, S.; Heninger, G. R.; Charney, D. S. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans Psychopharmacology 1999, 145, 193-204
150. Heresco-Levy, U.; Javitt, D. C.; Ermilov, M.; Mordel, C.; Horowitz, A.; Kelly, D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia Br. J. Psychiatry 1996, 169, 610-617
151. 11C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography Synapse 2010, 64, 542-549
152. 11C]CMPyPB, glycine transporter 1 (GlyT1) PET radiotracers Synapse 2011, 65, 261-270
153. Alberati, D.; Moreau, J. L.; Lengyel, J.; Hauser, N.; Mory, R.; Borroni, E.; Pinard, E.; Knoflach, F.; Schlotterbeck, G.; Hainzl, D.; Wettstein, J. G. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia Neuropharmacology 2012, 62, 1152-1161
154. Eddins, D.; Hamill, T. G.; Puri, V.; Cannon, C. E.; Vivian, J. A.; Sanabria-Bohorquez, S. M.; Cook, J. J.; Morrow, J. A.; Thomson, F.; Uslaner, J. M. The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey Psychopharmacology 2014, 231, 511-519
155. Martin-Facklam, M.; Pizzagalli, F.; Zhou, Y.; Ostrowitzki, S.; Raymont, V.; Brasic, J. R.; Parkar, N.; Umbricht, D.; Dannals, R. F.; Goldwater, R.; Wong, D. F. Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers Neuropsychopharmacology 2013, 38, 504-512
156. Siuciak, J. A. The role of phosphodiesterases in schizophrenia: therapeutic implications CNS Drugs 2008, 22, 983-993
157. Redrobe, J. P.; Jørgensen, M.; Christoffersen, C. T.; Montezinho, L. P.; Bastlund, J. F.; Carnerup, M.; Bundgaard, C.; Lerdrup, L.; Plath, N. In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia Psychopharmacology 2014, 231, 3151-3167
158. Andrés, J.-I.; De Angelis, M.; Alcazar, J.; Iturrino, L.; Langlois, X.; Dedeurwaerdere, S.; Lenaerts, I.; Vanhoof, G.; Celen, S.; Bormans, G. Synthesis, in vivo occupancy and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging J. Med. Chem. 2011, 54, 5820-5835
159. 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain J. Nucl. Med. 2010, 51, 1584-1591
160. 11C]methane with pyrylium salts J. Labelled Compd. Radiopharm. 2000, 43, 565-583
161. Lee, E.; Kamlet, A. S.; Powers, D. C.; Neumann, C. N.; Boursalian, G. B.; Furuya, T.; Choi, D. C.; Hooker, J. M.; Ritter, T. A fluoride-derived electrophilic late-stage fluorination reagent for PET imaging Science 2011, 334, 639-642